Nancy L. Lewis Appointed as New Chief Scientific Officer of NCCN

Nancy L. Lewis Takes the Helm as Chief Scientific Officer of NCCN

In a pivotal announcement, the National Comprehensive Cancer Network (NCCN), a prestigious alliance of leading cancer centers focused on improving patient care, research, and education, has appointed Dr. Nancy L. Lewis as its new Chief Scientific Officer (CSO). Dr. Lewis brings with her a wealth of experience and expertise in oncology, making her the ideal candidate to lead NCCN's mission to advance cancer care.

Dr. Lewis has a rich background in biomedical research, particularly in clinical trials for both solid tumors and hematologic malignancies. Her previous role as Senior Clinical Program Leader at Novartis Pharmaceuticals has equipped her with deep insights into the complexities of cancer treatment and research. In addition, she has served as an Associate Professor at several esteemed cancer centers, further establishing her as a leader in the field. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University, and completed her residency at the University of Rochester and a fellowship at the Fox Chase Cancer Center, one of NCCN's founding institutions.

Reflecting on her appointment, Dr. Crystal S. Denlinger, CEO of NCCN, stated, “This is a crucial moment for cancer research, and Dr. Lewis is perfectly positioned to lead our efforts to foster innovation and transform knowledge into action that benefits patients suffering from cancer.” With her leadership, NCCN aims to enhance the efficacy, quality, and accessibility of cancer care worldwide.

As the new CSO, Dr. Lewis will oversee key components of NCCN’s Oncology Research Program (ORP) and is set to play a vital role in the development and implementation of the NCCN Clinical Practice Guidelines in Oncology and the NCCN Guidelines for Patients. She will also have a hand in overseeing the NCCN Biomarkers Compendium, the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria. Dr. Lewis's influence will extend into the realms of continuing medical education and related global initiatives, positioning her as a cornerstone of NCCN’s future.

The accolades Dr. Lewis has received from prominent cancer organizations, including the American Association for Cancer Research and the American Society of Clinical Oncology, underscore her impact and contributions to the field. With her remarkable achievements and vision, Dr. Lewis is set to further enrich NCCN's commitment to delivering quality cancer care and improving outcomes for patients.

“I am excited to join the National Comprehensive Cancer Network and contribute to its legacy of advancing high-quality cancer care,” Dr. Lewis remarked. “I look forward to collaborating with an incredible team to address emerging challenges and foster innovative solutions for patients.”

Dr. Lewis will officially assume her role in May 2026, succeeding Dr. Denlinger, who previously held the position of CSO before her elevation to CEO. This transition points toward a strengthened leadership within NCCN, aimed at tackling one of the most pressing health issues today—cancer.

About NCCN

The National Comprehensive Cancer Network is a not-for-profit entity that unites leading cancer centers dedicated to patient care, research, and education. NCCN is committed to advancing quality, effective, equitable, and accessible cancer care and prevention. The NCCN Clinical Practice Guidelines serve as the definitive, evidence-based recommendations for cancer treatment and supportive services. They are regarded as the industry standard, providing comprehensive guidance that is perpetually updated to reflect the latest in medical advancements. Additionally, NCCN Guidelines for Patients offer crucial cancer treatment information to empower patients and their families, further emphasizing the organization's dedication to education and advocacy in oncology.

For more details on NCCN and its initiatives, browse to NCCN.org.